KALEIDO BIOSCIENCES, INC. [ 🌑 ] Shares of Common Stock Underwriting AgreementKaleido Biosciences, Inc. • November 21st, 2018 • Biological products, (no disgnostic substances) • New York
Kaleido Biosciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [ 🌑 ] shares of common stock, $0.001 par value per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [ 🌑 ] shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
KALEIDO BIOSCIENCES, INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENTDirector Indemnification Agreement • November 21st, 2018 • Kaleido Biosciences, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of [ ] by and between Kaleido Biosciences, Inc., a Delaware corporation (the “Company”), and [Director] (“Indemnitee”).
XCHANGE AT BEDFORD LEASE between and KALEIDO BIOSCIENCES, INC., as Tenant Bedford, Massachusetts As of May 15, 2017And Attornment Agreement • November 21st, 2018 • Kaleido Biosciences, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Lease is made and entered into as of May 15, 2017 by and between DIV BEDFORD, LLC, a Massachusetts limited liability company with its principal place of business at c/o The Davis Companies, 125 High Street, 21st Floor, Boston, Massachusetts 02110 (the “Landlord”) and KALEIDO BIOSCIENCES, INC., a Delaware corporation with its principal place of business at 18 Crosby Drive, Bedford, Massachusetts (the “Tenant”).
ContractKaleido Biosciences, Inc. • November 21st, 2018 • Biological products, (no disgnostic substances) • North Carolina
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH APPLICABLE LAW. THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 4 OF THIS WARRANT.
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTJoinder Agreement • November 21st, 2018 • Kaleido Biosciences, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of February 21, 2018, by and among Kaleido Biosciences, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto (each, an “Investor,” and together with any subsequent investors, or transferees, who become parties hereto as “Investors” pursuant to Subsection 6.9, the “Investors”).
